Improving uptake of the drug, a component of Paxlovid, could help reduce longer term outcomes, as well as severe disease, the authors said.
Nirmatrelvir tied to 26% lower risk of long COVID, 47% lower risk of death
More from COVID-19More posts in COVID-19 »
- FDA warns of false results from Cue Health COVID tests
- COVID patient testing, isolation of sick staff cut in-hospital viral spread, modeling study suggests
- TB-COVID co-infections increasingly common, tied to worse outcomes, data show
- Data: Heart-failure patients have 82% better odds of living longer if vaccinated against COVID